Merdury BioPharmaceutical Inc (Stock Code: 6932) has signed a technology platform licensing and commissioned development agreement with Shiner Pharmaceutical Corp. Under this agreement, Mercury BioPharmaceutical* will use its specific drug formulation technology to co-develop with Shiner an orally disintegrating tablet product intended for the treatment of erectile dysfunction (ED) and premature ejaculation (PE) in adult males, as well as handle the production and manufacturing upon completion of development. According to the terms of the licensing contract, Merdury BioPharmaceutical will receive a signing fee upon contract execution, followed by milestone payments based on the achievement of certain development milestones. The total of the signing fee and development milestone payments could reach up to NT$65 million. After the product is launched, Merdury BioPharmaceutical will also receive a fixed percentage of sales royalties.
This compound medication is currently only approved by the Central Drugs Standard Control Organization (CDSCO) of India in the form of a compound film-coated tablet, and it is the only such approved compound medication worldwide. Shiner has commissioned Merdury BioPharmaceutical to use its equipment, technology, and expertise to assist in the development of the product's formula and specifications, research and develop the production process and product analysis according to these specifications, provide the necessary related information, and assist in obtaining the drug registration/approvals by the Taiwan Food and Drug Administration (TFDA) to produce, manufacture, and distribute the product.
